Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Colorectal Cancer After ≥2 Lines of Chemotherapy Failure
ChiCTR-OPC-17010708Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: progression-free survival. Started Oct 2016; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-OPC-17010708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010708.